Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Bristol Expands Immunotherapy Footprint With Anti-PD-1

Jun 03 2012

• By Shirley Haley

Related Content

Poor Quality Data On Immune-Related Adverse Events Slowed <i>Yervoy</i> Review

Oct 01 2011

Yervoy Survival Data From First-Line Study Sealed The Deal For FDA Approval

Nov 28 2011

Related Companies

Bristol Myers Squibb Company

Additional Topics

BioPharmaceutical

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window